NEW YORK, Aug. 10, 2017 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ:OVID), a biopharmaceutical company committed to developing medicines for patients with rare neurological disorders, today announced financial results for the second quarter ended June 30, 2017 and provided an overview of the company’s recent business progress.
“Ovid continues to build a robust pipeline of promising medicines. We have made important progress over the last quarter in all our programs,” said Jeremy Levin, DPhil, MB BChir, chairman and chief executive officer of Ovid Therapeutics. “In collaboration with Takeda, we have rapidly advanced TAK935/OV935 into a Phase 1b/2a clinical trial in rare epilepsies.
